当前位置: 首页 > 详情页

Immunoassay of S-adenosylmethionine and S-adenosylhomocysteine: the methylation index as a biomarker for disease and health status

| 导出 | |

文献详情

资源类型:
机构: [1]Arthus Biosystems, 2600 Hilltop Dr., Richmond, CA 94806, USA. [2]Hunan SkyWorld Biotechnologies Co. Ltd, 9 Panpan Rd. Changsha Economic and Technological Development Zone, Changsha, Hunan 410100, China. [3]Department of Infectious Diseases, Xiangya Hospital, Central South University Hospital, Changsha, China. [4]Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China. [5]Changsha Blood Center, Changsha 410000, China. [6]Lanwei Clinical Laboratories Co. Ltd., 268 Xinxing Rd. International Enterprise Center Building 9, Suite 301, Yuhua District, Changsha 410000, China.
出处:
ISSN:

关键词: Antibody Biomarker Competitive ELISA Conjugates Diseases Immunoassay Methylation index S-Adenosylhomocysteine S-Adenosylmethionine

摘要:
Background: S-Adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are relevant to a variety of diseases. Previous reports that quantified SAM and SAH were based on HPLC or LC-MS/MS. No antibody against SAM has been generated, and the antibody against SAH cannot be used with blood samples. Immunoassays have not been used to measure SAM and SAH. In this study, ELISA was used to measure blood SAM and SAH levels. Results: Specific antibodies against SAM were produced for the first time using a stable analog as the antigen. The monoclonal antibodies against SAM and SAH were characterized. No cross-reactivity was detected for the analyzed analogs. For the anti-SAM antibodies, the ELISA sensitivity was -2 nM, and the affinity was 7.29 × 1010 L/mol. For the anti-SAH antibodies, the sensitivity was -15 nM, and the affinity was 2.79 × 108 L/mol. Using high-quality antibodies against SAM and SAH, immunoassays for the detection of SAM and SAH levels in blood and tissue samples were developed. Clinical investigations using immunoassays to measure SAM, SAH and the methylation index (MI) in normal and diseased samples indicated that (1) the SAM level is age and gender dependent; (2) the SAM level is associated with the severity of liver diseases, inflammatory reactions and other diseases; and (3) the methylation index (MI) is significantly reduced in many diseases and may serve as a screening biomarker to identify potentially unfavorable health conditions. Conclusion: It is possible to generate antibodies against active small biomolecules with weak immunogenicity, such as SAM and SAH, using traditional hybridoma technology. The antigens and antibodies described here will contribute to the development of immunoassays to measure SAM, SAH and related molecules. These assays enable the MI to be measured specifically, accurately, easily and quickly without costly equipment. This preliminary study indicates that the MI could be an effective indicator of general health, except under conditions that may alter the value of the MI, such as special diets and medications. © 2016 The Author(s)

基金:
语种:
PubmedID:
第一作者:
第一作者机构: [1]Arthus Biosystems, 2600 Hilltop Dr., Richmond, CA 94806, USA.
通讯作者:
通讯机构: [1]Arthus Biosystems, 2600 Hilltop Dr., Richmond, CA 94806, USA.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院